
Heska Corporation HSKA
Quarterly report 2023-Q1
added 05-05-2023
Heska Corporation Total Assets 2011-2026 | HSKA
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Heska Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 586 M | 604 M | 400 M | 244 M | 156 M | 136 M | 131 M | 110 M | 96.8 M | 93.6 M | 66.8 M | 61.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 604 M | 61.9 M | 224 M |
Quarterly Total Assets Heska Corporation
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 593 M | 586 M | 570 M | 587 M | 602 M | 604 M | 597 M | 579 M | 570 M | 400 M | 400 M | 400 M | 400 M | 244 M | 244 M | 244 M | 244 M | 156 M | 156 M | 156 M | 156 M | 135 M | 136 M | 136 M | 136 M | 131 M | 131 M | 131 M | 131 M | 110 M | 110 M | 110 M | 110 M | 96.8 M | 96.8 M | 96.8 M | 96.8 M | 93.6 M | 93.6 M | 93.6 M | 93.6 M | 66.8 M | 66.8 M | 66.8 M | 66.8 M | 61.9 M | 61.9 M | 61.9 M | 61.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 604 M | 61.9 M | 230 M |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Agilent Technologies
A
|
10.7 B | $ 115.48 | 0.82 % | $ 35.1 B | ||
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M | ||
|
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 16.2 | -0.61 % | $ 175 M | ||
|
Biodesix
BDSX
|
97.2 M | $ 15.07 | 2.1 % | $ 1.95 B | ||
|
Aspira Women's Health
AWH
|
5.46 M | - | -6.19 % | $ 10.5 M | ||
|
Co-Diagnostics
CODX
|
24.7 M | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Check-Cap Ltd.
CHEK
|
377 K | - | - | $ 9.42 M | ||
|
Castle Biosciences
CSTL
|
531 M | $ 24.84 | -0.84 % | $ 690 M | ||
|
DarioHealth Corp.
DRIO
|
110 M | $ 8.4 | 3.7 % | $ 33.5 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M | ||
|
BioNano Genomics
BNGO
|
73.6 M | $ 1.2 | 0.84 % | $ 6.53 M | ||
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M | ||
|
Charles River Laboratories International
CRL
|
7.14 B | $ 173.89 | -0.58 % | $ 8.62 B | ||
|
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | ||
|
DexCom
DXCM
|
6.34 B | $ 62.22 | -0.24 % | $ 24.3 B | ||
|
Fulgent Genetics
FLGT
|
1.22 B | $ 16.82 | 2.31 % | $ 509 M | ||
|
Biomerica
BMRA
|
5.94 M | $ 2.17 | -0.91 % | $ 4.98 M | ||
|
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M | ||
|
Celcuity
CELC
|
467 M | $ 112.63 | -0.27 % | $ 5.27 B | ||
|
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | ||
|
Exact Sciences Corporation
EXAS
|
5.86 B | - | - | $ 19.8 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | ||
|
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | ||
|
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 198.02 | 0.17 % | $ 22 B | ||
|
Guardant Health
GH
|
2.01 B | $ 93.83 | 2.94 % | $ 11.8 B | ||
|
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | ||
|
Lantheus Holdings
LNTH
|
2.23 B | $ 76.1 | 0.53 % | $ 5.14 B | ||
|
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | ||
|
Medpace Holdings
MEDP
|
1.98 B | $ 498.34 | 1.81 % | $ 14.4 B | ||
|
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | ||
|
Interpace Biosciences
IDXG
|
33.8 M | $ 1.96 | 5.82 % | $ 8.67 M | ||
|
Mettler-Toledo International
MTD
|
3.71 B | $ 1 259.94 | -1.11 % | $ 26 B | ||
|
ICON Public Limited Company
ICLR
|
16.9 B | $ 114.19 | 2.49 % | $ 9.42 B | ||
|
IDEXX Laboratories
IDXX
|
3.35 B | $ 569.55 | 0.87 % | $ 45.8 B | ||
|
Neogen Corporation
NEOG
|
3.44 B | $ 9.41 | 0.21 % | $ 2.04 B | ||
|
Illumina
ILMN
|
6.3 B | $ 127.38 | 0.59 % | $ 20.3 B | ||
|
IQVIA Holdings
IQV
|
29.9 B | $ 173.26 | 0.5 % | $ 29.8 B | ||
|
Pacific Biosciences of California
PACB
|
784 M | $ 1.34 | -0.74 % | $ 402 M | ||
|
Koninklijke Philips N.V.
PHG
|
26.9 B | $ 27.11 | -0.66 % | $ 20 B | ||
|
QIAGEN N.V.
QGEN
|
6.28 B | - | - | $ 10.6 B | ||
|
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | ||
|
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | ||
|
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 273.72 | 0.36 % | $ 22.8 B | ||
|
Myriad Genetics
MYGN
|
707 M | $ 4.75 | 3.49 % | $ 440 M | ||
|
Sotera Health Company
SHC
|
3.26 B | $ 14.96 | 0.61 % | $ 4.25 B | ||
|
NeoGenomics
NEO
|
1.36 B | $ 8.0 | 3.23 % | $ 1.02 B | ||
|
National Research Corporation
NRC
|
135 M | $ 17.16 | -1.04 % | $ 384 M |